These findings emphasize that, in a clinical setting, targeting EGFR and HER-2 simultaneously using Cet-TZ-PINs may not be sufficient for effective and complete tumor eradication in all patients, and thus the TR-PINs we present here, with an expanded specificity for a third tumor receptors are critical. Here, EGFR is linked to neoplasm.